A phase 1 study to evaluate the safety, pharmacology, and feasibility of continuous infusion nelarabine in patients with relapsed and/or refractory lymphoid malignancies
Boddu P, Senapati J, Ravandi‐Kashani F, Jabbour E, Jain N, Ayres M, Chen Y, Keating M, Kantarjian H, Gandhi V, Kadia T. A phase 1 study to evaluate the safety, pharmacology, and feasibility of continuous infusion nelarabine in patients with relapsed and/or refractory lymphoid malignancies. Cancer 2022, 129: 580-589. PMID: 36448227, DOI: 10.1002/cncr.34570.Peer-Reviewed Original ResearchConceptsPhase 1 studyT-cell prolymphocytic leukemiaComplete remissionContinuous infusionRefractory T-cell acute lymphoblastic leukemiaCentral nervous system toxicityIncomplete platelet recoveryRefractory lymphoid malignanciesT-cell acute lymphoblastic leukemiaUse of nelarabineFavorable clinical responseNervous system toxicityOverall response rateContinuous infusion scheduleAcute lymphoblastic leukemiaClinical responseCentral neurotoxicityLymphoblastic lymphomaMedian agePeripheral neuropathyInfusion scheduleSafety profilePatient populationLymphoblastic leukemiaPlatelet recovery
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply